CRISM Therapeutics Corporation (CRTX:AIM) delivered an investor update outlining substantial clinical and regulatory progress as it advances ChemoSeed, its proprietary localized drug-delivery platform designed to improve the safety, efficacy, and tumour-targeting precision of chemotherapy. Management highlighted strong momentum following an oversubscribed placing and current retail offer, enabling initiation of a Phase II registration-enabling trial for recurrent glioblastoma, an indication with no standard of care and significant unmet need. The MHRA has granted approval for an open-label study under the accelerated ILAP pathway, positioning the company for potential conditional market authorization upon demonstration of safety and an early efficacy signal. Manufacturing of the GMP clinical batch is underway, the CRO is engaged, and first patient dosing is expected in Q1 2025. ChemoSeed—paired with irinotecan—offers targeted delivery directly into the tumour margin, overcoming blood-brain-barrier limitations and dramatically reducing systemic toxicity. Preclinical survival data and prior Phase I safety findings support confidence in the mechanism. Success in glioblastoma could unlock broader solid tumour indications, including an emerging programme in prostate cancer. The company reiterated commitment to cost-appropriate pricing to avoid contributing to health-care inequality, while actively pursuing non-dilutive funding to support clinical execution. Despite market sensitivity around recent discounted fundraisings, management emphasized operational readiness, regulatory support, and a clear commercialisation strategy under evaluation, including independent launch or potential partnerships, with the UK representing an initial addressable market within a total estimated opportunity of £1.7bn across CNS indications.